Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of IL-6 in Exercise Recovery
NCT05349149Completed
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, double-blind trial of tocilizumab (2 arms). Primary endpoints: Change in muscle glycogen content, Change in muscle triglycerides content and 5 more. Started Apr 2022; status: completed.
02
Drugs
tocilizumab
Beyond the preview
Go deeper on NCT05349149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05349149.